Overview of injecting drug users living with HIV
Epidemiology of injecting drug users living with HIV
Mathers B, Degenhardt L, Adam P, et al. Estimating the level of HIV prevention coverage, knowledge and protective behavior among injecting drug users: what does the 2008 UNGASS reporting round tell us? J Acquir Immune Defic Syndr 2009;52(suppl 2):S132–142.
May M, Sterne JA, Sabin C, et al, for the Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007;21(9):1185–97.
van Sighem A, Danner S, Ghani A, et al. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr 2005;40:212–8.
Antiretroviral therapy and injecting drug users living with HIV
Weber R, Huber M, Rickenbach M, et al. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Medicine 2009;10:407–416.
Celentano D, Galai N, Sethi A, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;15:1707–1715.
Palepu A, Tyndall M, Yip B, et al. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003;32:522–526.
Clarke S, Delamere S, McCullough L, et al. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Medicine 2003;4:33–37.
Imprisonment and injecting drug users living with HIV
Alcohol use by injecting drug users living with HIV